[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY31997A - Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met. - Google Patents

Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met.

Info

Publication number
UY31997A
UY31997A UY0001031997A UY31997A UY31997A UY 31997 A UY31997 A UY 31997A UY 0001031997 A UY0001031997 A UY 0001031997A UY 31997 A UY31997 A UY 31997A UY 31997 A UY31997 A UY 31997A
Authority
UY
Uruguay
Prior art keywords
new
imidazo
inhibitors
met
piridina
Prior art date
Application number
UY0001031997A
Other languages
English (en)
Inventor
Patrick Nemecek
Damour Dominique
Nemecek Conception
Sylvie Wentzler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41382382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0804085A external-priority patent/FR2933981A1/fr
Priority claimed from FR0902409A external-priority patent/FR2945806B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31997A publication Critical patent/UY31997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La invención se refiere a los nuevos derivados de imidazo[1,2-]piridina de fórmula (I), estando estos productos en todas las formas isómeras y las sales, donde los radicales, sustituyentes y subíndices son tales como se especifican en la Memoria Descriptiva y en las Reivindicaciones, que presentan activadad anticancerosa, mediante la modulación de la actividad de proteínas, en particular, de quinasas. La invención se refiere también a procedimiento de preparación, composiciones farmacéuticas y a su uso como medicamentos principalmente como inhividores de MET. Se divulgan como productos industriales nuevos, los intermedios de síntesis.
UY0001031997A 2008-07-18 2009-07-17 Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met. UY31997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0804085A FR2933981A1 (fr) 2008-07-18 2008-07-18 NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
FR0902409A FR2945806B1 (fr) 2009-05-19 2009-05-19 Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met

Publications (1)

Publication Number Publication Date
UY31997A true UY31997A (es) 2010-02-26

Family

ID=41382382

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031997A UY31997A (es) 2008-07-18 2009-07-17 Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met.

Country Status (20)

Country Link
US (1) US20110257171A1 (es)
EP (1) EP2318382A1 (es)
JP (1) JP2011528338A (es)
KR (1) KR20110039559A (es)
CN (1) CN102159559A (es)
AR (1) AR072518A1 (es)
AU (1) AU2009272517A1 (es)
BR (1) BRPI0915924A2 (es)
CA (1) CA2730749A1 (es)
CL (1) CL2011000116A1 (es)
CO (1) CO6331467A2 (es)
EA (1) EA201170223A1 (es)
IL (1) IL210689A0 (es)
MA (1) MA32565B1 (es)
MX (1) MX2011000675A (es)
PE (1) PE20110572A1 (es)
TW (1) TW201006839A (es)
UY (1) UY31997A (es)
WO (1) WO2010007317A1 (es)
ZA (1) ZA201100429B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2011103018A1 (en) 2010-02-18 2011-08-25 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
CN102690264B (zh) * 2012-06-20 2014-07-02 泰山医学院 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法
CN104619709B (zh) * 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
CN109863137B (zh) 2016-10-26 2022-12-16 星座制药公司 Lsd1抑制剂及其医学用途
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024126404A1 (en) * 2022-12-14 2024-06-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2785157A (en) * 1952-11-05 1957-03-12 Eastman Kodak Co Benzothiazoleazoaniline compounds
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
BR0108085A (pt) * 2000-02-07 2003-03-18 Abbott Gmbh & Co Kg Derivados de 2-benzotiazolil uréia e seu uso como inibidores da cinase protéica
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2212323B1 (en) * 2007-10-17 2012-08-15 Novartis AG Imidazo [1,2-a] pyridine derivatives useful as alk inhibitors

Also Published As

Publication number Publication date
IL210689A0 (en) 2011-03-31
WO2010007317A1 (fr) 2010-01-21
TW201006839A (en) 2010-02-16
ZA201100429B (en) 2012-03-28
MX2011000675A (es) 2011-04-11
US20110257171A1 (en) 2011-10-20
PE20110572A1 (es) 2011-08-25
MA32565B1 (fr) 2011-08-01
CN102159559A (zh) 2011-08-17
EA201170223A1 (ru) 2011-08-30
CO6331467A2 (es) 2011-10-20
CA2730749A1 (fr) 2010-01-21
JP2011528338A (ja) 2011-11-17
BRPI0915924A2 (pt) 2015-10-27
CL2011000116A1 (es) 2011-06-17
AR072518A1 (es) 2010-09-01
KR20110039559A (ko) 2011-04-19
EP2318382A1 (fr) 2011-05-11
AU2009272517A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
UY31997A (es) Nuevos derivados de imidazo[1,2-a]piridina, y sus nuevos usos como inhibidores de met.
UY31996A (es) Nuevos derivados de triazolo[4,3-a]piridina, y sus nuevos usos como inhibidores de met
UY31998A (es) Nuevos derivados de imidazo[1,2-a]pirimidina, y sus nuevos usos como inhibidores de met
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
CL2018001671A1 (es) Derivados de pirimidina 4-amino-2-(1h-pirazolo[3,4-b]piridina-3-yl)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d] y los derivados respectivos (1h-indazol-3-yl) como moduladores cgmp para el tratamiento de enfermedades cardiovasculares.
UY30859A1 (es) Nuevos derivados de 2-anilino-4-heteroarilpirimidinas , su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
PE20150883A1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
UY31729A (es) Derivados polisustituidos de 2-heteroaril-6-fenil-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapeútica
ECSP14013215A (es) Compuestos novedosos
UY32754A (es) NUEVOS DERIVADOS DE 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
ECSP13012404A (es) Derivados anticancerosos, su preparación y su aplicación terapéutica
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
GT201400007A (es) Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores
UY32275A (es) DERIVADOS DE AZACARBOLINAS 9H-PIRROLO[2,3-b:5,4-c'] DIPIRIDINA, SU PREPARACION Y SU UTILIZACIÓN TERAPÉUTICA.
UY32753A (es) NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA
CO2018012020A2 (es) Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3
UY32422A (es) Derivados de 6-(6-sustituido-triazlopiridacina-sulfanil) 5-fluoro-benzotiazololes y 5-fluoro-bencimidazoles : preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met
UY30417A1 (es) Derivados de aril y heteroaril-etil-acilguanidina,su preparacion y su aplicacion en terapeutica
UY31972A (es) Derivados anticancerosos, su preparación y su aplicación en terapéutica
UY32421A (es) Derivados de 6-(triazolopiridazinsulfanil sustituido en 6-nh) benzotiazoles y bencimidazoles: preparacion, aplicacion como medicamentos y utilizacion como inhibidores de met

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140519